News
Teva Settlement Stalls Austedo Generic Rollout Till 2033
Austedo, Teva's tardive dyskinesia (TD) therapy, has great prospects. Now the company only needs to worry about one less generic pharmaceutical presenting a threat to its main growth engine.Teva announced recently that it had reached an agreement with Lupin that...
News
60% Adults And 75% Kids Have COVID-19 Antibodies- CDC Study
According to updated information from the US Centers for Disease Control and Prevention, about 60% of adults plus 75% of children have antibodies suggesting that they've been exposed to COVID-19.
The information comes from a long-term examination of blood...
News
Camzyos, A Likely Blockbuster Heart Drug, Wins FDA Approval
Bristol Myers Squibb has gained approval for one of the year's most anticipated medications, following a brief delay in November. Camzyos, a drug developed by Bristol Myers Squibb, was approved by the FDA to cure symptomatic obstructive hypertrophic cardiomyopathy,...
News
New programme celebrates ChargePoint Technology’s role in COVID-19 vaccine rollout
Specialist Merseyside manufacturing business ChargePoint Technology is set to appear in an ITN production exploring its role in helping to bring the first COVID-19 vaccine to market.
The company will feature in the upcoming programme “How Vaccines Are Changing The...
News
Rinvoq, Blockbuster Drug From Abbvie Gets Fourth FDA Nod
The pharma version of Fast and Furious has a new superhero. How else to characterise AbbVie's Rinvoq's breakthrough effectiveness? The immunology medicine received its fourth FDA approval in five months on April 29th for ankylosing spondylitis. The blessing, however, came...
News
Starting The Journey Dupixent From Sanofi Puts A Good Show
Sanofi's Dupixent is still breaking new ground in inflammatory illnesses five years after receiving FDA approval for the first time in eczema. Bill Sibold, Sanofi's global head of speciality care, believes this since the Regeneron-partnered drug's first-quarter sales increased...
News
Carcinogen Concern Leads To Pfizer Drug Recall From The US
Pfizer's recall saga has now reached the United States, after elevated concentrations of potential carcinogens forced the company to pull multiple products in Canada. After testing revealed quantities of a nitrosamine—Nnitroso-quinapril—above daily recommended limits, Pfizer is recalling five lots...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read